Robert Driscoll
Stock Analyst at Wedbush
(1.87)
# 2,946
Out of 4,778 analysts
156
Total ratings
29.5%
Success rate
-8.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $5.66 | +200.35% | 4 | Mar 21, 2025 | |
| HOWL Werewolf Therapeutics | Reiterates: Outperform | $8 | $1.08 | +640.74% | 2 | Mar 12, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $8.13 | +47.60% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $8.28 | +286.47% | 6 | Feb 26, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $34 → $36 | $7.13 | +405.26% | 8 | Feb 6, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $18.03 | +188.41% | 9 | Dec 17, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $67 | $38.46 | +74.21% | 4 | Dec 6, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $10.32 | +171.32% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $1.69 | +846.75% | 10 | Oct 8, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Outperform | $30 | $8.40 | +257.14% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.25 | +1,660.00% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $6.10 | +736.07% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.89 | +464.84% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $8.30 | +333.73% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.18 | +404.59% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $4 | $1.87 | +114.48% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.98 | +226.63% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $1.64 | +692.68% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $30.92 | +139.33% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.16 | +270.37% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.71 | +310.56% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $0.62 | +1,200.81% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.28 | +2,716.90% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $10.71 | +385.53% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.37 | +18.69% | 4 | May 19, 2020 |
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $5.66
Upside: +200.35%
Werewolf Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.08
Upside: +640.74%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $8.13
Upside: +47.60%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $8.28
Upside: +286.47%
Kura Oncology
Feb 6, 2025
Maintains: Outperform
Price Target: $34 → $36
Current: $7.13
Upside: +405.26%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $18.03
Upside: +188.41%
Revolution Medicines
Dec 6, 2024
Maintains: Outperform
Price Target: $70 → $67
Current: $38.46
Upside: +74.21%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $10.32
Upside: +171.32%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $1.69
Upside: +846.75%
Arcus Biosciences
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $8.40
Upside: +257.14%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.25
Upside: +1,660.00%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $6.10
Upside: +736.07%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.89
Upside: +464.84%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $8.30
Upside: +333.73%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.18
Upside: +404.59%
Aug 12, 2024
Upgrades: Neutral
Price Target: $4
Current: $1.87
Upside: +114.48%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $3.98
Upside: +226.63%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $1.64
Upside: +692.68%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $30.92
Upside: +139.33%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.16
Upside: +270.37%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.71
Upside: +310.56%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $0.62
Upside: +1,200.81%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.28
Upside: +2,716.90%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $10.71
Upside: +385.53%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.37
Upside: +18.69%